She noted the beneficial therapeutic effects of blocking antibodies targeting the PD-1/PD-L1 pathway in bladder cancer, while emphasizing that anti-PD-L1 treatments (atezolizumab) were only active in subsets of patients (33). Here, CD274 is linked to urinary bladder cancer.